Collaboration in the race to find a Covid-19 vaccine
Tania Shapiro-Barr says in order to mitigate the IP risks during collaboration over Covid-19 vaccine developments, a balance must be struck between sharing and protecting IP
Tania Shapiro-Barr MD/JD - Dykema
As the world eagerly awaits the introduction of a vaccine for Covid-19, all eyes are on the life sciences industry. More
than ever before, biopharmaceutical scientists and researchers are working together to fight the pandemic. This collaboration
is key to the rapid development of a safe and effective vaccine. In order for open collaboration and sharing of intellectual
property to continue in the life sciences arena, however, it must operate within the existing legal framework for IP protection.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.